Botulinum Toxin Type A for the Treatment of Nummular Headache: Four Case Studies
Authors:
- 11 December 2007
- journal article
- case report
- Published by Wiley in Headache: The Journal of Head and Face Pain
- Vol. 48 (3) , 442-447
Abstract
Objective.— We assessed the efficacy and safety of botulinum toxin type A (BoNTA; BOTOX ® : Allergan, Inc., Irvine, CA, USA) in patients with nummular headache who did not respond to other treatments including nonsteroidal anti‐inflammatory drugs (NSAIDs), local anesthetics, and/or gabapentin. Background.— Nummular headache is characterized by circumscribed round or elliptical areas of fluctuating mild‐to‐moderate head pain in a chronic or remitting pattern. It is a relatively rare primary headache disorder that responds poorly to adequate treatment trials with local anesthetic, migraine, or neuropathic pain agents or NSAIDs. Methods.— Four patients aged 35‐58 years with intractable nummular headaches were given 25 units of BoNTA divided among 10 injection sites in and around the circumscribed affected areas of pain, paresthesia, and allodynia. All patients had 2 sets of injections approximately 14 weeks apart. Results.— All patients met the International Headache Society criteria for nummular headache (International Classification of Headache Disorders, A13.7.1). Patients were female; mean age of onset was 42 years. Average disease duration prior to BoNTA treatment was 3.75 years. One patient reported concurrent episodic migraine and another reported concurrent tension‐type headache. Patients reported round‐shaped (n = 2; 6 and 3 cm in diameter), oval (n = 1; 4 × 2 cm), and elliptical (n = 1; 6 cm in length) areas of pain. Painful symptoms were reported in the right parietal convexity (n = 2) and the posterior frontal, unilaterally (n = 2). All patients experienced spontaneous or stimuli‐triggered exacerbations and variable combinations of sensory disturbances, including allodynia, tenderness, and paresthesia. The temporal pattern was continuous in 3 patients and intermittent in one. Both the size and shape of the pain remained unchanged in all patients since the onset of nummular headache symptoms. Six to 10 days following BoNTA treatment, all patients experienced a reduction in nummular headache symptoms, which lasted approximately 14 weeks on average. Repeat injections gave the same degree of improvement. No treatment‐related adverse events were reported. Conclusions.— BoNTA appears to be a well‐tolerated effective treatment for intractable, persistent nummular headache in patients with an inadequate response to other treatments including NSAIDs, gabapentin, or local anesthetics.Keywords
This publication has 18 references indexed in Scilit:
- A Multicentre, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study of Multiple Treatments of Botulinum Toxin Type A (BoNTA) for the Prophylaxis of Episodic Migraine HeadachesCephalalgia, 2007
- Local Decrease of Pressure Pain Threshold in Nummular HeadacheHeadache: The Journal of Head and Face Pain, 2006
- Nummular HeadacheCephalalgia, 2006
- Botulinum Toxin Type A (BOTOX ® ) for the Prophylactic Treatment of Chronic Daily Headache: A Randomized, Double‐Blind, Placebo‐Controlled TrialHeadache: The Journal of Head and Face Pain, 2005
- Botulinum Toxin A in the Prophylactic Treatment of Migraine – A Randomized, Double-Blind, Placebo-Controlled StudyCephalalgia, 2004
- Nummular Headache: A Prospective Series of 14 New CasesHeadache: The Journal of Head and Face Pain, 2004
- Regulation of Calcitonin Gene‐Related Peptide Secretion From Trigeminal Nerve Cells by Botulinum Toxin Type A: Implications for Migraine TherapyHeadache: The Journal of Head and Face Pain, 2004
- Pharmacology and immunology of botulinum toxin type AClinics in Dermatology, 2003
- Nummular headache: diagnosis and treatmentExpert Review of Neurotherapeutics, 2003
- Botulinum Toxin Type A as a Migraine Preventive TreatmentHeadache: The Journal of Head and Face Pain, 2000